Results 11 to 20 of about 1,795 (145)

Emicizumab-induced photosensitivity

TH Open, 2022
Emicizumab constitutes a novel and effective prophylaxis for hemophilia A patients with and without inhibitors. In this case report, we describe an emicizumab-induced photosensitivity that forced permanent sun-exposure suppression.
Pedro Asensi Cantó, Mercedes Rodríguez Serna, Pilar Lloret Madrid, Jürgen Solís Ruiz, Ana Rosa Cid Haro, Santiago Bonanad Boix, Saturnino Haya Guaita   +6 more
doaj   +3 more sources

Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed.
Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Sara Arcudi, Roberta Gualtierotti, Cristina Novembrino, Flora Peyvandi   +6 more
doaj   +2 more sources

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis [PDF]

Haematologica
Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against factor VIII (FVIII). Emicizumab mimics the activity of FVIIIa restoring thrombin generation.
Fabius J. Pelzer, Ella I. Ertekin, Olga Oleshko, Annika Klingberg, Paul Knöbl, Christian Pfrepper, Richard Greil, Johannes Oldenburg, Ulrich J. Sachs, Wolfgang Miesbach, Karolin Trautmann-Grill, Katharina Holstein, Hermann Eichler, Patrick Möhnle, Christina Hart, Robert Klamroth, Andreas Tiede, Sonja Werwitzke   +17 more
doaj   +2 more sources

No correlation between thrombin generation and emicizumab levels: implications for monitoring emicizumab therapy

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab, a bispecific antibody that mimics factor (F)VIII, has significantly improved hemophilia A management. Although emicizumab levels can be measured, tools for estimating the hemostatic efficacy of emicizumab are lacking.
Konrad van der Zwet, Mark Roest, Dana Huskens, Roger E.G. Schutgens, Lize F.D. van Vulpen, Kathelijn Fischer, Rolf T. Urbanus   +6 more
doaj   +3 more sources

Emicizumab Associated Rhabdomyolysis in Hemophilia A [PDF]

Clinical Hematology International, 2020
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation.
Joseph A. Wilson, Stephanie Hayden, Alexander Asamoah, Vivek R. Sharma, David C. Jennings, Ashok B. Raj   +5 more
doaj   +3 more sources

Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Denecimig (Mim8, Novo Nordisk A/S) is a next-generation bispecific antibody designed to mimic activated factor (F)VIII and restore hemostasis in persons with hemophilia A.
Jacob Lund, Mirella Ezban, Kasper Jensen, David Lillicrap   +3 more
doaj   +2 more sources

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis [PDF]

Blood Advances
: Intracranial hemorrhage (ICH) and resulting neurologic disability are severe complications for a subset of infants with severe hemophilia A (HA). Although prophylactic factor replacement reduces bleeding risk, it is typically delayed until after age 1 ...
Samira Glaeser-Khan, Satoko Ito, Manraj Sra, Rhys Richmond, Robert D. Bona, Harlan M. Krumholz, Stacy E. Croteau, Adam Cuker, George Goshua   +8 more
doaj   +2 more sources

Emicizumab prophylaxis in current haemophilia A care in the Czech Republic—data from the Czech National Haemophilia Programme Registry [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Nonfactor therapy with emicizumab has become an important part of the haemophilia A treatment landscape recently. Objectives: We aimed to analyze data on the transition from previous treatment regimens to emicizumab in routine clinical ...
Ester Zápotocká, Petra Ovesná, Bohumír Blažek, Zuzana Čermáková, Zdeňka Hajšmanová, Radomíra Hrdličková, Petr Birke, Daniela Procházková, Petr Smejkal, Jan Blatný   +9 more
doaj   +2 more sources

A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC

Hematology, Transfusion and Cell Therapy, 2023
Aim: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is a gene therapy evaluated in the phase 3 GENEr8-1 trial that provides endogenous factor VIII (FVIII) production to prevent bleeding in people with severe hemophilia A and represents an alternative to ...
W Kuwabara, D Osmond, J Henshaw, S Agarwal, V Newman, C Hermans, W Miesbach, S Pipe, RS Jr, F Peyvandi   +9 more
doaj   +1 more source

Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

Haematologica, 2023
Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of ...
Thibaud Sefiane, Hortense Maynadié, Carmen Escurola Ettingshausen, Vincent Muczynski, Xavier Heiligenstein, Julien Dumont, Olivier D. Christophe, Cécile V. Denis, Caterina Casari, Peter J. Lenting   +9 more
doaj   +1 more source